To this aim, several strategies might be explored to generate effective therapies, such as the use of low-dose chemotherapy, able to abrogate MDSC proliferation, accumulation and function [56, 57]; or, specific antibodies that limit myeloid migration into the tumor, such as monoclonal antibodies to CSF-1 receptor (CSF-1R), or antibodies to CCR2 and to CXCR4 [58], as well as the use of antibodies able to restrain tumor-induced inflammation (i.e. anti-IL-6 antibody). This evidence concerns the gene IL6 and neoplasm.